Good EULAR Response In Patients With Early Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal clinical setting in Greece

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Etanercept; Methotrexate

Criteria

Inclusion Criteria:

1. signed and dated informed consent document

2. 18 years of age and older at the time of consent

3. Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria

4. Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC,

5. Patients with DAS28 ≥ 3.2

6. Duration of disease symptoms ≥ 6 weeks and ≤2 years

7. Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice.

Exclusion Criteria:

1. Contraindications according to the SmPC

2. History of or present anti-TNFa or other biologic therapy for the treatment of RA

3. Known significant concurrent medical disease according to investigator's opinion and the current SmPC